The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss
Real World Outcome of Eculizumab in Post-Kidney Transplant TMA
16 responses
Loading...
This form is approaching the response limit. Once surpassed, the summary of responses will no longer be displayed. Learn more
Close
This form has exceeded 50,000 responses and the summary of responses can no longer be displayed. You can still download responses as a .csv file. Learn more
Kindly fill out a separate Google Form/link for each patient
A. Center and respondent details
1. Name of transplant center
No responses yet for this question.
2. City/state/country
City
No responses yet for this question.
State
No responses yet for this question.
Country
No responses yet for this question.
3. Type of Center
No responses yet for this question.
4. Annual Kidney Transplant Volume
No responses yet for this question.
5. Respondent Name/Designation
No responses yet for this question.
6. Contact - Email ID
No responses yet for this question.
7.
Contact - Mobile Number
No responses yet for this question.
8. Does your center maintain a transplant TMA registry?
No responses yet for this question.
B. Incidence and Prevalence
1. Total
kidney transplants performed in last 5 years:
No responses yet for this question.
2. Number of suspected post-transplant TMA cases:
No responses yet for this question.
3. Number
of biopsy-proven TMA cases:
No responses yet for this question.
4. Number of systemic TMA cases:
No responses yet for this question.
5. Number of kidney-limited TMA cases:
No responses yet for this question.
6. Timing of TMA after transplant:
No responses yet for this question.
7. Classification:
No responses yet for this question.
C. Recipient and Transplant Details
1. Recipient Age
No responses yet for this question.
2. Recipient Gender
No responses yet for this question.
3. Native Kidney Disease
No responses yet for this question.
4. History
of TMA/aHUS before Transplant
No responses yet for this question.
5. Previous Graft Loss due to TMA
No responses yet for this question.
6. Donor Type
No responses yet for this question.
7. HLA Mismatch
No responses yet for this question.
8. DSA
present Pre-Transplant
No responses yet for this question.
9. Induction Used
No responses yet for this question.
10. Maintenance Immunosuppression
No responses yet for this question.
11. CNI/mTOR trough level at TMA diagnosis
No responses yet for this question.
D.
Clinical presentation
1. Presentation
No responses yet for this question.
2. Serum Creatinine at Diagnosis
No responses yet for this question.
3. Urine
protein/Creatinine ratio
No responses yet for this question.
4. BP
at Diagnosis
No responses yet for this question.
5. Need
for Dialysis
No responses yet for this question.
E. Laboratory Diagnosis
1. Hemoglobin
No responses yet for this question.
2. Platelet Count
No responses yet for this question.
3. LDH
No responses yet for this question.
4. Haptoglobin
No responses yet for this question.
5. Reticulocyte Count
No responses yet for this question.
6.
Schistocytes
on Peripheral Smear
No responses yet for this question.
7. Direct
Coombs test
No responses yet for this question.
8.
C3
No responses yet for this question.
9. C4
No responses yet for this question.
10. ADAMTS13
activity tested
No responses yet for this question.
IF YES:
RESULT
RESULT
No responses yet for this question.
11. STEC/Shiga
toxin testing done
No responses yet for this question.
IF YES:
RESULT
RESULT
No responses yet for this question.
12. Other Infection Identified
No responses yet for this question.
13. Anti-factor
H Antibody Tested
No responses yet for this question.
IF YES:
RESULT
RESULT
No responses yet for this question.
14. Complement Genetic Testing Done
No responses yet for this question.
IF YES:
No responses yet for this question.
15. Variant
classification
No responses yet for this question.
F.
Biopsy and Rejection Assessment
1. Graft Biopsy Performed
No responses yet for this question.
2. Biopsy
timing from TMA Suspicion
No responses yet for this question.
3. Biopsy
findings:
No responses yet for this question.
4. C4d
staining
No responses yet for this question.
5. Microvascular Inflammation
No responses yet for this question.
6. DSA
at Diagnosis
No responses yet for this question.
7. ABMR Diagnosed
No responses yet for this question.
8. TCMR
present
No responses yet for this question.
9. Electron Microscopy Done
No responses yet for this question.
10. Final
biopsy impression
No responses yet for this question.
G.
Suspected trigger
1. Most
likely trigger
No responses yet for this question.
2. Was
more than one trigger present?
No responses yet for this question.
H.
Treatment details
1. Initial Management
No responses yet for this question.
2.
Was Eculizumab Used?
No responses yet for this question.
3. Indication
for Eculizumab
No responses yet for this question.
4. Time
from Diagnosis to First Eculizumab Dose
No responses yet for this question.
5. Eculizumab
Dosing Schedule Used
No responses yet for this question.
6. Number
of Doses
No responses yet for this question.
7. Duration
of Therapy
No responses yet for this question.
8. Was Ravulizumab Used Later?
No responses yet for this question.
9. Reason
for stopping eculizumab
No responses yet for this question.
10. Vaccination
before Eculizumab
No responses yet for this question.
11. Antibiotic
prophylaxis given?
No responses yet for this question.
12. Funding
source
No responses yet for this question.
I.
Outcomes
1. Hematological Response
No responses yet for this question.
2. Platelet Recovery Day
No responses yet for this question.
3.
LDH Normalization Day
No responses yet for this question.
4.
Creatinine
at 1 Month
No responses yet for this question.
5.
Creatinine
at 3 Months
No responses yet for this question.
6.
Creatinine
at 6 Months
No responses yet for this question.
7.
Creatinine
at 12 Months
No responses yet for this question.
8.
Dialysis Discontinued?
No responses yet for this question.
9.
Graft Outcome
No responses yet for this question.
10.
TMA Recurrence after Treatment Withdrawal
No responses yet for this question.
11.
Infection
after Eculizumab
No responses yet for this question.
If Yes
Kindly name the infection
Kindly name the infection
No responses yet for this question.
12.
Other Adverse Events
No responses yet for this question.
13.
Mortality
No responses yet for this question.
J.
Real-world Barriers and Opinion
1.
Main Barriers to Eculizumab Use
No responses yet for this question.
2. In which Cases would you Consider Eculizumab?
No responses yet for this question.
3. Do you support Creating a National Post-Transplant TMA Registry?
No responses yet for this question.
4.
Are
you Willing to Contribute Anonymized Cases?
No responses yet for this question.
Waiting for responses
This content is neither created nor endorsed by Google. - Terms of Service - Privacy Policy
Does this form look suspicious? Report
